Mirai Bio

Catch the Mirai team at #BIO International 2025 next week in Boston! For more information visit our website (https://www.miraibio.com/) or contact us at info@miraibio.com

Join us this afternoon at the TIDES: Oligonucleotides and Peptide Therapeutics Conference where Mirai Bio's Head of Platform, Dr. Jagesh Shah will present as part of a panel on Next Generation Delivery Platforms. Catch the panel at 4:15 PM PDT in Solana Beach, Level 3 of the Manchester Grand Hyatt, San Diego. #geneticmedicines #celltherapy #invivo #delivery

This deal unites Thermo Fisher’s developmental and cGMP services, commercial manufacturing capabilities and global capacity with Mirai’s innovative technology platform for optimizing the design, delivery and development of novel nucleic acid therapeutics. Our own Michael Laska will lead the collaboration, which enhances Mirai’s end-to-end platform capabilities available to its partners. https://lnkd.in/gH6Kv5Qw

Join us tomorrow at #PEGS where Mirai Bio's Head of Platform, Dr. Jagesh Shah will present as part of a panel on Next Generation Immunotherapy: In Vivo Approaches. Catch the panel at 2:30 PM in Momentum C at the Omni Hotel, Boston. #geneticmedicines #celltherapy #invivo #delivery

Mirai President & COO, Jens H. Vogel, Ph.D. joined the Flagship Pioneering studio at #JPM to describe how we are working to advance the #delivery of #geneticmedicines and why Mirai is positioned to work with partners across biotech and pharma looking to optimize performance and accelerate development of any genetic medicine. Watch the full chat here: https://lnkd.in/gYYDcCBc

BioCentury Inc. has highlighted Mirai Bio in its Emerging Companies series, emphasizing our integration of nucleic acid design, #delivery, and #manufacturing, which enables biotech partners to focus on validating #therapies without worrying about production logistics. The article features our barcoding and custom microfluidics systems as components of our comprehensive aim to drive innovative non-viral delivery solutions. #CGT #geneticmedicines  Check out the article here: https://lnkd.in/grU7dQPy

Mirai Bio President and COO, Jens H. Vogel, Ph.D. captures the scalability challenges facing #celltherapies in this Cell & Gene Therapy Insights article, exploring innovative solutions like in vivo engineering to expand patient access and streamline production.

This weekend we celebrate the innovative #cellandgenetherapy research exhibited at #ASH2024. Mirai Bio is the development partner of choice for any biotech seeking to optimize performance and accelerate translation of any #geneticmedicine from concept to the clinic. Learn more about our capabilities on our website: https://www.miraibio.com/

Today we welcome Jens H. Vogel, Ph.D. as President and COO of Mirai Bio. As a global leader in all aspects of biopharmaceutical development, platform innovation, and end-to-end technical operations, Dr. Vogel will guide the Company’s growth and platform development as it expands partnerships with companies across the biotech industry who are seeking to develop novel #GeneticMedicines. https://lnkd.in/g3Bwimbj

Find our Head of Corporate Development Scott Ugras at Pharma Partnering Summit tomorrow and Thursday to learn more about Mirai Bio, a Flagship Pioneering company #geneticmedicines #drugdelivery #CGT #celltherapy #genetherapy #geneediting